Lipid metabolism and cardiovascular risk in HIV-1 infection and HAART: Present and future problems

Cholesterol

Volumn 2010, Issue , 2010, Pages

  Melzi, Sara ^a   Carenzi, Laura ^a   Cossu, Maria Vittoria ^a   Passerini, Simone ^a   Capetti, Amedeo ^a   Rizzardini, Giuliano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FENOFIBRATE; FISH OIL; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NELFINAVIR; NEVIRAPINE; PLACEBO; PRAVASTATIN; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMVASTATIN;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79955083727     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2010/271504     Document Type: Review

References (87)

1. Danesh J., Collins R., Peto R., Chronic infections and coronary heart disease: is there a link? The Lancet 1997 350 9075 430 436 (Pubitemid 27331246)
2. Mattila K. J., Valtonen V. V., Nieminen M. S., Asikainen S., Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke Clinical Infectious Diseases 1998 26 3 719 734 (Pubitemid 28155027)
3. Epstein S. E., Zhou Y. F., Zhu J., Infection and atherosclerosis: emerging mechanistic paradigms Circulation 1999 100 4 e20 e28
4. Meier C. R., Jick S. S., Derby L. E., Vasilakis C., Jick H., Acute respiratory-tract infections and risk of first-time acute myocardial infarction The Lancet 1998 351 9114 1467 1471 (Pubitemid 28227037)
5. Grunfeld C., Feingold K. R., Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense Proceedings of the Society for Experimental Biology and Medicine 1992 200 2 224 227
6. Leinonen M., Saikku P., Evidence for infectious agents in cardiovascular disease and atherosclerosis Lancet Infectious Diseases 2002 2 1 11 17 (Pubitemid 36109301)
7. Zhu J., Quyyumi A. A., Norman J. E., Csako G., Waclawiw M. A., Shearer G. M., Epstein S. E., Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels American Journal of Cardiology 2000 85 2 140 146 (Pubitemid 30026092)
8. Roivainen M., Alfthan G., Jousilahti P., Kimpimki M., Hovi T., Tuomilehto J., Enterovirus infections as a possible risk factor for myocardial infarction Circulation 1998 98 23 2534 2537 (Pubitemid 29001191)
9. Broxmeyer L., Heart disease: the greatest 'risk' factor of them all Medical Hypotheses 2004 62 5 773 779 (Pubitemid 38530339)
10. Rasheed S., Yan J. S., Lau A., Chan A. S., HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study PLoS ONE 2008 3 8
11. Hellerstein M. K., Grunfeld C., Wu K., Christiansen M., Kaempfer S., Kletke C., Shackleton C. H. L., Increased de novo hepatic lipogenesis in human immunodeficiency virus infection Journal of Clinical Endocrinology and Metabolism 1993 76 3 559 565 (Pubitemid 23086466)
12. Riddler S. A., Smit E., Cole S. R., Li R., Chmiel J. S., Dobs A., Palella F., Visscher B., Evans R., Kingsley L. A., Impact of HIV infection and HAART on serum lipids in men Journal of the American Medical Association 2003 289 22 2978 2982 (Pubitemid 37430100)
13. Anderson J. L., Infection, antibiotics, and atherothrombosisend of the road or new beginnings? The New England Journal of Medicine 2005 352 16 1706 1709
14. Cicognani C., Malavolti M., Morselli-Labate A. M., Zamboni L., Sama C., Barbara L., Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis Archives of Internal Medicine 1997 157 7 792 796 (Pubitemid 27164455)
15. Currier J. S., Lundgren J. D., Carr A., Klein D., Sabin C. A., Sax P. E., Schouten J. T., Smieja M., Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy Circulation 2008 118 2 e29 e35
16. Lai S., Fishman E. K., Lai H., Moore R., Cofrancesco J. Jr., Pannu H., Tong W., Du J., Bartlett J., Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms Clinical Infectious Diseases 2008 46 4 600 610 (Pubitemid 351263503)
17. Martnez E., Milinkovic A., Buira E., De Lazzari E., Len A., Larrousse M., Lonc M., Laguno M., Blanco J. L., Mallolas J., Garca F., Mir J. M., Gatell J. M., Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area HIV Medicine 2007 8 4 251 258 (Pubitemid 46695372)
18. Eugenin E. A., Morgello S., Klotman M. E., Mosoian A., Lento P. A., Berman J. W., Schecter A. D., Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease American Journal of Pathology 2008 172 4 1100 1111 (Pubitemid 351520006)
19. Torriani F. J., Komarow L., Parker R. A., Cotter B. R., Currier J. S., Dub M. P., Fichtenbaum C. J., Gerschenson M., Mitchell C. K. C., Murphy R. L., Squires K., Stein J. H., Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. The ACTG (AIDS Clinical Trials Group) study 5152s Journal of the American College of Cardiology 2008 52 7 569 576
20. Francisci D., Giannini S., Baldelli F., Leone M., Belfiori B., Guglielmini G., Malincarne L., Gresele P., HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction AIDS 2009 23 5 589 596
21. SMART Study Group, CD4+-guided interruption of antiretroviral treatment The New England Journal of Medicine 2006 355 2283 2296
22. Tebas P., Henry W. K., Matining R., Weng-Cherng D., Schmitz J., Valdez H., Jahed N., Myers L., Powderly W. G., Katzenstein D., Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk PLoS ONE 2008 3 4
23. Friis-Mller N., Reiss P., Sabin C. A., Weber R., Monforte A. D., El-Sadr W., Thibaut R., De Wit S., Kirk O., Fontas E., Law M. G., Phillips A., Lundgren J. D., Class of antiretroviral drugs and the risk of myocardial infarction The New England Journal of Medicine 2007 356 17 1723 1735 (Pubitemid 46658704)
24. Worm S. W., Sabin C., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M., Monforte A. D., Friis-Mller N., Kirk O., Fontas E., Weller I., Phillips A., Lundgren J., Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study Journal of Infectious Diseases 2010 201 3 318 330
25. Cooper D., Bloch M., Humphries A., Simplification with fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in adults with suppressed HIV replication: the STEAL study, a randomized, open-label, 96-week, non-inferiority trial Proceedings of the 16th Conference on Retroviruses and. Opportunistic Infections (CROI '10) February 2009 Montral, Canada. abstract no. 576
26. Martnez E., Arranz J. A., Podzamczer D., Lonc M., Sanz J., Barragn P., Ribera E., Knobel H., Roca V., Gutirrez F., Blanco J. L., Mallolas J., Llibre J. M., Clotet B., Dalmau D., Segura F., Arribas J. R., Cosn J., Barrufet P., Casas E., Ferrer E., Curran A., Gonzlez A., Pich J., Cruceta A., Arnaiz J. A., Mir J. M., Gatell J. M., A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression Journal of Acquired Immune Deficiency Syndromes 2009 51 3 290 297
27. Sax P. E., Tierney C., Collier A. C., Fischl M. A., Mollan K., Peeples L., Godfrey C., Jahed N. C., Myers L., Katzenstein D., Farajallah A., Rooney J. F., Ha B., Woodward W. C., Koletar S. L., Johnson V. A., Geiseler P. J., Daar E. S., Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy The New England Journal of Medicine 2009 361 23 2230 2240
28. Walmsley S., Avihingsanon A., Slim J., Ward D. J., Ruxrungtham K., Brunetta J., Bredeek U. F., Jayaweera D., Guittari C. J., Larson P., Schutz M., Raffi F., Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-I therapy in adults Journal of Acquired Immune Deficiency Syndromes 2009 50 4 367 374
29. Eron J. Jr., Yeni P., Gathe J. Jr., Estrada V., DeJesus E., Staszewski S., Lackey P., Katlama C., Young B., Yau L., Sutherland-Phillips D., Wannamaker P., Vavro C., Patel L., Yeo J., Shaefer M., The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial The Lancet 2006 368 9534 476 482 (Pubitemid 44160731)
30. Molina J.-M., Andrade-Villanueva J., Echevarria J., Chetchotisakd P., Corral J., David N., Moyle G., Mancini M., Percival L., Yang R., Wirtz V., Lataillade M., Absalon J., McGrath D., Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-nave HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study Journal of Acquired Immune Deficiency Syndromes 2010 53 3 323 332
31. Mills A. M., Nelson M., Jayaweera D., Ruxrungtham K., Cassetti I., Girard P.-M., Workman C., Dierynck I., Sekar V., Abeele C. V., Lavreys L., Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS 2009 23 13 1679 1688
32. Dub M. P., Stein J. H., Aberg J. A., Fichtenbaum C. J., Gerber J. G., Tashima K. T., Henry W. K., Currier J. S., Sprecher D., Glesby M. J., Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clinical Infectious Diseases 2003 37 5 613 627 (Pubitemid 37100800)
33. http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 1TreatmentofHIVInfectedAdults.pdf
34. Milinkovic A., Martinez E., Lpez S., De Lazzari E., Mir O., Vidal S., Blanco J. L., Garrabou G., Laguno M., Arnaiz J. A., Leon A., Larrousse M., Lonca M., Mallolas J., Gatell J. M., The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients Antiviral Therapy 2007 12 3 407 415 (Pubitemid 46787986)
35. Llibre J. M., Domingo P., Palacios R., Santos J., Prez-Elas M. J., Snchez-De La Rosa R., Miralles C., Antela A., Moreno S., Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir AIDS 2006 20 10 1407 1414 (Pubitemid 43948247)
36. Vigan A., Aldrovandi G. M., Giacomet V., Merlo M., Martelli L., Beretta S., Luraschi P., Rombol G., Mora S., Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children Antiviral Therapy 2005 10 8 917 924 (Pubitemid 43076343)
37. Salmon-Ceron D., Lazzarin A., Van Wijngaerden E., Antunes F., Leen C., Horban A., Wirtz V., Odeshoo L., Van Den Dungen M., Gruber C., Ledesma E., Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results Clinical Infectious Diseases 2007 44 11 1484 1492 (Pubitemid 46801594)
38. Class G. J., Jlg B., Rling J., Goebel F. D., Bogner J. R., Metabolic and anthropometric changes one year after switching from Didanosine/Stavudine to Tenofovir in HIV-infected patients European Journal of Medical Research 2007 12 2 54 60 (Pubitemid 46394639)
39. Valantin M. A., Bittar R., de Truchis P., Bollens D., Slama L., Giral P., Bonnefont-Rousselot D., Ptour P., Aubron-Olivier C., Costagliola D., Katlama C., Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate+emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients Journal of Antimicrobial Chemotherapy 2010 65 3 556 561
40. Parienti J.-J., Massari V., Rey D., Poubeau P., Verdon R., Efavirenz to nevirapine switch in HIV-1infected patients with dyslipidemia: a randomized, controlled study Clinical Infectious Diseases 2007 45 2 263 266 (Pubitemid 47041021)
41. Eron J. J., Young B., Cooper D. A., Youle M., DeJesus E., Andrade-Villanueva J., Workman C., Zajdenverg R., Ftkenheuer G., Berger D. S., Kumar P. N., Rodgers A. J., Shaughnessy M. A., Walker M. L., Barnard R. J., Miller M. D., DiNubile M. J., Nguyen B.-Y., Leavitt R., Xu X., Sklar P., Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir- based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials The Lancet 2010 375 9712 396 407
42. Tebas P., Zhang J., Yarasheski K., Evans S., Fischl M. A., Shevitz A., Feinberg J., Collier A. C., Shikuma C., Brizz B., Sattler F., Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s) Journal of Acquired Immune Deficiency Syndromes 2007 45 2 193 200 (Pubitemid 46869812)
43. Busti A. J., Bedimo R., Margolis D. M., Hardin D. S., Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir Journal of Investigative Medicine 2008 56 2 539 544
44. Mallolas J., Podzamczer D., Milinkovic A., Domingo P., Clotet B., Ribera E., Gutirrez F., Knobel H., Cosin J., Ferrer E., Arranz J. A., Roca V., Vidal F., Murillas J., Pich J., Pedrol E., Llibre J. M., Dalmau D., Garca I., Aranda M., Cruceta A., Martnez E., Blanco J. L., Lazzari E. D., Gatell J. M., Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a lpv/r-containing haart: the atazip study Journal of Acquired Immune Deficiency Syndromes 2009 51 1 29 36
45. Nguyen S. T., Eaton S. A., Bain A. M., Rahman A. P., Payne K. D., Bedimo R., Herrington J. D., Maclayton D. O., Rodriguez-Barradas M. C., Busti A. J., Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus Pharmacotherapy 2008 28 3 323 330 (Pubitemid 351328905)
46. Soriano V., Garca-Gasco P., Vispo E., Ruiz-Sancho A., Blanco F., Martn-Carbonero L., Rodrguez-Novoa S., Morello J., De Mendoza C., Rivas P., Barreiro P., Gonzlez-Lahoz J., Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial Journal of Antimicrobial Chemotherapy 2008 61 1 200 205
47. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Journal of the American Medical Association 2001 285 19 2486 2497 (Pubitemid 32433843)
48. Tungsiripat M., Aberg J. A., Dyslipidemia in HIV patients Cleveland Clinic Journal of Medicine 2005 72 12 1113 1120
49. Sekar V., Spinosa-Guzman S., Marien K., Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin Proceedings of the 8th International Workshop on Clinical Pharmacology of HIV Therapy April 2007 Budapest, Hungary. abstract no. 54
50. Fichtenbaum C. J., Gerber J. G., Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection Clinical Pharmacokinetics 2002 41 14 1195 1211 (Pubitemid 35398692)
51. Moyle G. J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard B. G., Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy AIDS 2001 15 12 1503 1508 (Pubitemid 32744597)
52. Gerber J. G., Rosenkranz S. L., Fichtenbaum C. J., Vega J. M., Yang A., Alston B. L., Brobst S. W., Segal Y., Aberg J. A., Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study Journal of Acquired Immune Deficiency Syndromes 2005 39 3 307 312 (Pubitemid 40923210)
53. Kiser J. J., Gerber J. G., Predhomme J. A., Wolfe P., Flynn D. M., Hoody D. W., Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers Journal of Acquired Immune Deficiency Syndromes 2008 47 5 570 578 (Pubitemid 351442013)
54. van der Lee M., Sankatsing R., Schippers E., Vogel M., Ftkenheuer G., Van Der Ven A., Kroon F., Rockstroh J., Wyen C., Bumer A., De Groot E., Koopmans P., Stroes E., Reiss P., Burger D., Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients Antiviral Therapy 2007 12 7 1127 1132 (Pubitemid 350114993)
55. De Lorenzo F., Boffito M., Collot-Teixeira S., Gazzard B., McGregor J. L., Shotliff K., Xiao H., Prevention of atherosclerosis in patients living with HIV Vascular Health and Risk Management 2009 5 1 287 300
56. Negredo E., Molt J., Puig J., Cinquegrana D., Bonjoch A., Prez-lvarez N., Lpez-Blzquez R., Blanco A., Clotet B., Rey-Joly C., Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins AIDS 2006 20 17 2159 2164 (Pubitemid 44684706)
57. Wohl D., Hsue P., Richard S., Ezetimibes effects on the LDL cholesterol levels of HIV-infected patients receiving HAART Proceedings of the 14th Conference on Retroviruses and. Opportunistic Infections (CROI '07) 2007 Los Angeles, Calif, USA. abstract no. 39
58. Bennett M. T., Johns K. W., Bondy G. P., Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV Lipids in Health and Disease 2007 6
59. Miller J., Brown D., Amin J., Kent-Hughes J., Law M., Kaldor J., Cooper D. A., Carr A., A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia AIDS 2002 16 16 2195 2200 (Pubitemid 35387274)
60. Aberg J. A., Zackin R. A., Brobst S. W., Evans S. R., Alston B. L., Henry W. K., Glesby M. J., Torriani F. J., Yang Y., Owens S. I., Fichtenbaum C. J., A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group study 5087 AIDS Research and Human Retroviruses 2005 21 9 757 767 (Pubitemid 41434180)
61. Fichtenbaum C. J., Yeh T.-M., Evans S. R., Changes in markers of atherogenic dyslipidemia, inflammation, and platelet activation with treatment with pravastatin, fenofibrate, or the combination: results from ACTG A5087 Proceedings of the 15th Conference on Retroviruses and. Opportunistic Infections (CROI '08) 2008 Boston, Mass, USA. abstract no. 932
62. Silverberg M. J., Levden W., Hurley L., Go A. S., Quesenberry C. P. Jr., Klein D., Horberg M. A., Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection Annals of Internal Medicine 2009 150 5 301 313
63. Gerber J. G., Kitch D. W., Fichtenbaum C. J., Zackin R. A., Charles S., Hogg E., Acosta E. P., Connick E., Wohl D., Kojic E. M., Benson C. A., Aberg J. A., Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 Journal of Acquired Immune Deficiency Syndromes 2008 47 4 459 466 (Pubitemid 351366958)
64. De Truchis P., Kirstetter M., Perier A., Meunier C., Zucman D., Force G., Doll J., Katlama C., Rozenbaum W., Masson H., Gardette J., Melchior J.-C., Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study Journal of Acquired Immune Deficiency Syndromes 2007 44 3 278 285 (Pubitemid 46328343)
65. Carosi G., Quiros-Roldan E., Torti C., Antinori A., Bevilacqua M., Bonadonna R. C., Bonfanti P., Castagna A., Cauda R., D'Arminio-Monforte A., Di Gregorio P., Di Perri G., Esposito R., Fatuzzo F., Gervasoni C., Giannattasio C., Guaraldi G., Lazzarin A., Lo Caputo S., Maggi P., Mazzotta F., Moroni M., Prestileo T., Ranieri R., Rizzardini G., Russo R., Galli M., First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) Infection 2007 35 3 134 142 (Pubitemid 46932334)
66. Behrens G. M. N., Reiss P., Abacavir and cardiovascular risk Current Opinion in Infectious Diseases 2010 23 1 9 14
67. Arribas Lpez J. R., Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker Enfermedades Infecciosas y Microbiologa Clnica 2008 26 supplement 11 23 27
68. Keiser P. H., Sension M. G., DeJesus E., Rodriguez A., Olliffe J. F., Williams V. C., Wakeford J. H., Snidow J. W., Shachoy-Clark A. D., Fleming J. W., Pakes G. E., Hernandez J. E., Substituting abacavir for hyperlipidemia- associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment BMC Infectious Diseases 2005 5 1, article 2
69. Katlama C., Gazzard B., Mallolas J., Schrmann D., Moroni M., Demonty N., Antoun Z., Gordon D., Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy AIDS 2003 17 12 1855 1856 (Pubitemid 37000106)
70. Lafeuillade A., Clumeck N., Mallolas J., Jaeger H., Livrozet J.-M., do Sameira Ferreira M., Johnson M., Cheret A., Antoun Z., Demonty J., Bazin C., Bentata M., Bouvet E., Delfraissy J. F., Dellamonica P., Saint Marc T., De Saint Martin L., De Truchis P., Dien G., Gallais H., Gil H., Hoen B., Katlama C., Lacoste D., Lang J. M., Livrozet J. M., Beumont M., Massip P., Rozenbaum W., Sereni D., Yeni P., Fenske S., Rockstroh J., Salzberger B., Schuermann D., Staszewski S., Mulcahy F., Lazzarin A., Milazzo F., Moroni M., Cargnel A., Santos C., Flamholc L., Koppel K., Easterbrook P., Fisher M., Gazzard B., Kinghorn G., Weber J., Wilkins E., Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the trizal study HIV Clinical Trials 2003 4 1 37 43 (Pubitemid 36336096)
71. Rizzardini G., Capetti A., Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review Medical Science Monitor 2006 12 12 RA269 RA276
72. Martnez E., Arnaiz J. A., Podzamczer D., Dalmau D., Ribera E., Domingo P., Knobel H., Riera M., Pedrol E., Force L., Llibre J. M., Segura F., Richart C., Corts C., Javaloyas M., Aranda M., Cruceta A., De Lazzari E., Gatell J. M., Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection The New England Journal of Medicine 2003 349 11 1036 1046 (Pubitemid 37087618)
73. Negredo E., Cruz L., Paredes R., Ruiz L., Fumaz C. R., Bonjoch A., Gel S., Tuldr A., Balagu M., Johnston S., Arn A., Jou A., Tural C., Sirera G., Romeu J., Clotet B., Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression Clinical Infectious Diseases 2002 34 4 504 510 (Pubitemid 34112272)
74. Ruiz L., Negredo E., Domingo P., Paredes R., Francia E., Balagu M., Gel S., Bonjoch A., Fumaz C. R., Johnston S., Romeu J., Lange J., Clotet B., Antiretroviral treatment simplification with nevirapine in protease inhibitorexperienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study Journal of Acquired Immune Deficiency Syndromes 2001 27 3 229 236 (Pubitemid 32661963)
75. Petit J. M., Duong M., Masson D., Buisson M., Duvillard L., Bour J. B., Brindisi M. C., Galland F., Guiguet M., Gambert P., Portier H., Vergs B., Serum adiponectin and metabolic parameters in HIV-I-infected patients after substitution of nevirapine for protease inhibitors European Journal of Clinical Investigation 2004 34 8 569 575 (Pubitemid 39120227)
76. Gonzalez-Tome M. I., Amador J. T. R., Pea J. M., Gomez M. L. N., Conejo P. R., Fontelos P. M., Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children BMC Infectious Diseases 2008 8
77. Estrada V., De Villar N. G. P., Larrad M. T. M., Lpez A. G., Fernndez C., Serrano-Rios M., Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy Clinical Infectious Diseases 2002 35 1 69 76 (Pubitemid 34666862)
78. Ward D. J., Curtin J. M., Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles AIDS Patient Care and STDs 2006 20 8 542 548 (Pubitemid 44769201)
79. Schewe C. K., Maserati R., Wassmer G., Adam A., Weitner L., Improved lipid profiles and maintenance of virologic control in heavily pretreated hiv-infected patients who switched from stavudine to tenofovir treatment Clinical Infectious Diseases 2006 42 1 145 147 (Pubitemid 41832094)
80. Madruga J. V. R., Cassetti I., Suleiman J. M. A. H., Etzel A., Zhong L., Holmes C. B., Cheng A. K., Enejosa J., The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy HIV Clinical Trials 2007 8 6 381 390 (Pubitemid 350305212)
81. Ananworanich J., Nuesch R., Ct H. C. F., Kerr S. J., Hill A., Jupimai T., Laopraynak N., Saenawat S., Ruxrungtham K., Hirschel B., Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudinea staccato trial substudy Journal of Antimicrobial Chemotherapy 2008 61 6 1340 1343 (Pubitemid 351753605)
82. Ribera E., Paradieiro J. C., Curran A., Sauleda S., Garca-Arum E., Castella E., Puiggrs C., Crespo M., Feijoo M., Diaz M., del Saz S. V., Planas M., Sureda D., Falc V., Ocaa I., Pahissa A., Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study) HIV Clinical Trials 2008 9 6 407 417
83. Mbius U., Lubach-Ruitman M., Castro-Frenzel B., Stoll M., Esser S., Voigt E., Christensen S., Rump J.-A., Ftkenheuer G., Behrens G. M. N., Schmidt R. E., Switching to atazanavir improves metabolic disorders in antiretroviral- experienced patients with severe hyperlipidemia Journal of Acquired Immune Deficiency Syndromes 2005 39 2 174 180 (Pubitemid 40741115)
84. Sension M., De Andrade Neto J. L., Grinsztejn B., Molina J. M., Zavala I., Gonzlez-Garca J., Donnelly A., Phiri P., Ledesma E., McGrath D., Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir Journal of Acquired Immune Deficiency Syndromes 2009 51 2 153 162
85. Flammer A. J., Vo N. T. T., Ledergerber B., Hermann F., Gmperli A., Huttner A., Evison J., Baumgartner I., Cavassini M., Hayoz D., Quitzau K., Hersberger M., Sudano I., Ruschitzka F., Lscher T. F., Noll G., Weber R., Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial Heart 2009 95 5 385 390
86. Murphy R. L., Berzins B., Zala C., Fichtenbaum C., Dube M. P., Guaraldi G., Torriani F., Belsey E., Mitchell C., Stein J. H., Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy AIDS 2010 24 6 885 890
87. Colafigli M., Di Giambenedetto S., Bracciale L., Tamburrini E., Cauda R., De Luca A., Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen HIV Medicine 2008 9 3 172 179 (Pubitemid 351283132)